Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.74 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.74 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.74 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.74 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.74 |
| ▸ | MEN1 | O00255 | 3/20 | 0.60 |
| ▸ | MAPT | P10636 | 3/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.60 |
| ▸ | USP2 | O75604 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | THRB | P10828 | 1/20 | 0.60 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.60 |
| ▸ | APEX1 | P27695 | 1/20 | 0.60 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.60 |
| ▸ | RECQL | P46063 | 1/20 | 0.60 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27754841 | 0.86 | HDAC1 (0.59) | HDAC6HDAC1HDAC2HDAC8HDAC9 | |
| SCHEMBL11977114 | 0.86 | HDAC1 (0.59) | HDAC6HDAC1HDAC2HDAC8HDAC9 | |
| SCHEMBL12472344 | 0.85 | HDAC6 (0.73) | HDAC6HDAC1HDAC2HDAC8HDAC9 | |
| SCHEMBL15705724 | 0.85 | HDAC6 (0.81) | HDAC6HDAC1HDAC2HDAC8HDAC9 | |
| SCHEMBL12472553 | 0.85 | HDAC6 (1.00) | HDAC6HDAC1HDAC2HDAC8HDAC9 | |
| SCHEMBL6821030 | 0.85 | HDAC1 (0.62) | HDAC6HDAC1HDAC2HDAC8HDAC9 | |
| SCHEMBL30049411 | 0.85 | HDAC1 (0.62) | HDAC6HDAC1HDAC2HDAC8HDAC9 | |
| Hydrochloric Acid SCHEMBL29595575 | 0.84 | HDAC1 (0.57) | HDAC6HDAC1HDAC2HDAC8HDAC9 | |
| SCHEMBL12850688 | 0.84 | HDAC6 (0.67) | HDAC6HDAC1HDAC2HDAC8HDAC9 | |
| SCHEMBL2824971 | 0.82 | HDAC6 (0.64) | HDAC6HDAC1HDAC2HDAC8HDAC9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1397137-B1 | HYDANTION DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES | BRISTOL MYERS SQUIBB CO (US) | 2009-10-14 | — | — | EP | disclosed |
| US-7482372-B2 | Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE) | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-01-27 | — | — | US | disclosed |
| US-20050171096-A1 | Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE) | SHEPPECK JAMES E (US) | 2005-08-04 | — | — | US | disclosed |
| US-6906053-B2 | Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE) | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-06-14 | — | — | US | disclosed |
| US-6890915-B2 | Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE) | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-05-10 | — | — | US | disclosed |
| US-20040209874-A1 | Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE) | SHEPPECK JAMES E (US) | 2004-10-21 | — | — | US | disclosed |
| EP-1397137-A4 | HYDANTION DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES | BRISTOL MYERS SQUIBB CO (US) | 2004-10-13 | — | — | EP | disclosed |
| EP-1397137-A1 | HYDANTION DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-03-17 | — | — | EP | disclosed |
| US-20030130273-A1 | Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE) | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-07-10 | — | — | US | disclosed |
| WO-2002096426-A1 | HYDANTION DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-12-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209874-A1 | Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE) | ADAM17, ADAMTS1, ADAM8 | HDAC6 225/4885HDAC1 85/4885HDAC2 312/4885 |
| US-20050171096-A1 | Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE) | ADAM17, ADAMTS1, ADAM9 | HDAC6 251/4885HDAC1 88/4885HDAC2 386/4885 |
| US-20030130273-A1 | Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE) | ADAM17, ADAMTS1, ADAM8 | HDAC6 225/4885HDAC1 85/4885HDAC2 312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.